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Abstract
The genetic loci that have been found by genome-wide association studies to modulate risk of coronary heart disease
explain only a fraction of its total variance, and gene-gene interactions have been proposed as a potential source of the
remaining heritability. Given the potentially large testing burden, we sought to enrich our search space with real
interactions by analyzing variants that may be more likely to interact on the basis of two distinct hypotheses: a biological
hypothesis, under which MI risk is modulated by interactions between variants that are known to be relevant for its risk
factors; and a statistical hypothesis, under which interacting variants individually show weak marginal association with MI. In
a discovery sample of 2,967 cases of early-onset myocardial infarction (MI) and 3,075 controls from the MIGen study, we
performed pair-wise SNP interaction testing using a logistic regression framework. Despite having reasonable power to
detect interaction effects of plausible magnitudes, we observed no statistically significant evidence of interaction under
these hypotheses, and no clear consistency between the top results in our discovery sample and those in a large validation
sample of 1,766 cases of coronary heart disease and 2,938 controls from the Wellcome Trust Case-Control Consortium. Our
results do not support the existence of strong interaction effects as a common risk factor for MI. Within the scope of the
hypotheses we have explored, this study places a modest upper limit on the magnitude that epistatic risk effects are likely
to have at the population level (odds ratio for MI risk 1.3–2.0, depending on allele frequency and interaction model).
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Introduction
Coronary heart disease (CHD) is a leading cause of death and
disability worldwide [1], and is characterized by significant
heritability [2]. While genome wide association (GWA) studies
have identified several genetic markers associated with CHD risk
and cardiovascular risk factors, the observed effect sizes of these
variants are generally smaller than may have been expected, and
account for only a small fraction of the variance in disease risk (e.g.
,10% for CHD [3]). The marked familial clustering we observe in
PLoS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e41730the general population suggests the presence of heritable risk
factors with large effects that GWAS are not designed to detect,
such as rare variants or gene-gene interactions (epistasis), among
others [4].
The GWAS approach has had some success for most complex
phenotypes studied to date thanks to the fact that at least some loci
have sufficiently strong risk effects to overcome the multiple-testing
burden. However, it seems likely that true epistasis effects will
constitute a much smaller fraction of the potential search space
than for single loci, and this problem is exacerbated by the fact
that the compound genotypes that carry additional risk through
interaction will generally be less frequent, since their frequency is
the product of that of their component single-locus genotypes
(under linkage equilibrium). Our success in detecting these
interaction effects relies on their being strong enough to overcome
the decrease in power due to their lower frequencies and the
amplified multiple testing burden. As for single-locus variants
before the beginning of the GWAS era, the likely range of risk
effects that gene-gene interactions might have is unknown a priori
for complex phenotypes.
Given the practical challenges of carrying out epistasis analyses
on GWAS data, various statistical approaches to this problem have
been proposed and computational tools developed (reviewed by
Cordell [5]). Of the relatively limited number of attempts that
have been made to address this question at a genome-wide level
for complex phenotypes, the majority have tried to alleviate the
multiple-testing burden by searching for interactions among a
reduced number of variants that are considered more likely to
interact on the basis of some hypothesis, such as pathway-directed
or candidate variant approaches (e.g. [6,7,8]), or have otherwise
attempted to minimize the computational burden (e.g. [9,10]). As
far as we are aware, these efforts have not resulted in the discovery
of robust gene-gene interaction effects for any of the complex
phenotypes investigated.
In this study, we addressed the hypothesis that gene-gene
interactions contribute to the risk of early-onset myocardial
infarction (MI). From a genome-wide panel, we selected single
nucleotide polymorphisms (SNPs) that were hypothesized to be
more likely to modulate risk of MI through interaction because (i)
they have been shown to be robustly associated with cardiovas-
cular risk factors (CVRF) or clinical endpoints (CHD or MI), or
because (ii) they show weak marginal association with MI. We
tested for pair-wise interaction between these SNPs to attempt to
identify epistatic effects that could partly explain the missing
heritability of MI risk.
Methods
A general outline of the design of this study is shown in Figure 1.
An extended description of the methods is given in File S1, and
summarized below. Sections, tables and figures in File S1 are
indicated in parentheses throughout the manuscript (File S1
Section X.X, Supporting Table X and Supporting Figure X,
respectively).
Ethics Statement
This study was approved by the Clinical Research Ethics
Committee of Parc de Salut MAR, Barcelona.
Study Design and Subjects (File S1 Section 1)
In this study we performed a discovery analysis of gene-gene
interactions using genotype data from the Myocardial Infarction
Genetics Consortium (MIGen) [11], consisting of 2,967 cases of
early-onset myocardial infarction (men #50 or women #60 years
old), diagnosed on the basis of autopsy evidence, a combination of
chest pain and electrocardiographic evidence, or elevation of
cardiac biomarkers, and 3,075 age- and sex-matched controls. We
validated our top results in a sample of participants from the
Wellcome Trust Case Control Consortium [12], consisting of
1,766 cases with a validated history of either MI or coronary
revascularization (coronary artery bypass surgery or percutaneous
coronary angioplasty) before the age of 66, and 2,938 controls.
Genome-wide genotype data and associated phenotype data for
the MIGen sample was obtained via The Database of Genotypes
and Phenotypes (dbGaP; http://dbgap.ncbi.nlm.nih.gov; project
number #2120). All participants gave written informed consent to
be included in these studies [11,12].
SNP Selection (File S1 Section 2)
We selected SNPs for interaction testing under two hypotheses:
i) interactions that modulate MI risk are more likely to occur
between SNPs that are individually associated with CVRFs or
cardiovascular clinical endpoints (hereafter called CVRF SNPs)
than between SNPs that are not known to be associated with these
phenotypes; ii) SNPs that modulate MI risk via interaction with
other SNPs will show at least a low level of marginal association
with MI in the MIGen study (hereafter called marginal SNPs).
CVRF SNPs (File S1 Sections 2.1–2.3). We identified SNPs
reported to be associated with CVRFs or cardiovascular clinical
endpoints by filtering the NHGRI catalogue of GWA studies [13]
and mining data from a series of recently published large meta-
analyses of GWA studies (see File S1 Supporting Figure 1 for a
summary of the literature search and SNP selection process, and
File S1 Supporting Table 1 for references). From these studies we
identified SNPs that were strongly associated (p,5610
28) with the
reported phenotype, and grouped these into 10 categories broadly
definable as distinct CVRFs or cardiovascular endpoints (File S1
Supporting Figure 1). These were LDL cholesterol, HDL
cholesterol, Triglycerides, Smoking, Blood Pressure, Carbohydrate
Metabolism (including Type 2 Diabetes and related traits, e.g.
fasting glucose), Obesity/Body Mass, Plasma LP(a) levels, LDL
particle size (SNPs reported to be associated with relative
concentrations of small, atherogenic LDL particles [14]), and
Myocardial Infarction or Coronary Heart Disease (File S1
Supporting Table 1). MI/CHD-associated variation in the LPA
gene was represented by the haplotypes reported by Tre ´goue ¨t et al.
[15] (File S1 Section 3.7, File S1 Section 9).
Marginal SNPs (File S1 Section 2.4). We also selected
SNPs that achieved an arbitrary p-value of #10
23 or #10
22 for
association with MI in the MIGen study.
We tested for interaction among CVRF SNPs (Analysis 1),
between CVRF SNPs and SNPs with moderate marginal
association with MI (p#10
23; Analysis 2), and among SNPs with
moderate to weak marginal association with MI (p#10
23, Analysis
3a; p#10
22, Analysis 3b) (Figure 1; File S1 Supporting Figure 2).
Statistical Analysis (File S1 Section 3)
Interaction analyses were performed using two different tests
(File S1 Section 3.3). In Analyses 1–2, we used a case-control test
that assumed no specific interaction model but simply contrasted
the frequencies of the 9 two-locus genotypes in cases to those in
controls [16] by comparing the fits of logistic regression models
with and without interaction terms (Test A). We also used this test
to verify the results for the most significant interactions from all
Analyses in a validation sample from the WTCCC, and performed
a fixed effects meta-analysis of both studies (File S1 Section 3.8).
To test for interactions between Lp(a) haplotypes and other SNPs,
we implemented the same testing framework in a model that also
Gene-Gene Interaction Analysis in MI
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3.7). Due to the greater computational burden of Analyses 3a and
3b, we used a more approximate but faster allelic interaction test
implemented in PLINK [17], which compares the correlation
between alleles among cases to that among controls (Test B); as a
result of the genotype collapsing procedure used in this test and the
low minor allele frequencies (MAF) of some SNPs, some SNP pairs
could not be compared using this test (File S1 Section 3.3). We also
performed case-control/case-only and logic regression analyses as
alternative approaches to searching for epistasis in these data; the
methods and results of these analyses are detailed in File S1 Notes
1 and 2, respectively.
Within each Analysis, we tested for interaction only between
SNPs that were mutually independent (LD r
2,0.5; File S1 Section
3.2); we also avoided redundancy between Analyses by eliminating
SNPs that were in LD (r
2$0.5) with SNPs from a previous
Analysis (File S1 Section 3.2). We accounted for multiple testing
within each Analysis by setting the threshold required to declare a
significant result as the 95
th percentile of the expected distribution
of the most significant p-value for all interaction pairs [18] under
the null hypothesis that two-locus compound genotypes do not
modify MI risk. These top results follow a beta distribution, the
parameters of which were estimated by performing up to 10,000
permutations of each analysis with randomized MI status (Figure 2;
File S1 Section 3.4, File S1 Supporting Figure 3). For the purposes
of creating quantile-quantile plots, we used the permuted results to
compute the expected distribution of ranked test results under the
null hypothesis (Figure 2; File S1 Section 3.5, File S1 Supporting
Figure 3). We expressed the power of our study in terms of the
interaction effect sizes it has 80% power to detect. This was
calculated for SNP pairs representing the entire range of observed
MAFs and for various interaction models (Figure 2; File S1 Section
3.6, File S1 Supporting Figure 3; and Discussion); the results of the
power calculations under an additive6additive interaction model
are indicated below for each Analysis. All statistical analyses were
carried out using packaged or custom functions written in R v2.11
(R Foundation for Statistical Computing, Vienna [19]), or using
PLINK v1.07 [17], where indicated. This report adheres to the
recommendations of the STREGA statement on the reporting of
genetic association studies [20]; the GWAS studies on which this
work is based were completed and/or published before this
statement was released, and represent rigorous work reported in a
manner consistent with these recommendations.
Results
Analysis 1, Tests for Interaction among CVRF SNPs
From the literature sources described above, we identified 242
independent SNPs reported to be robustly associated with CVRFs
or cardiovascular endpoints; these SNPs, the reported phenotypes,
and the p-values for association with MI in the MIGen study are
shown in File S1 Supporting Table 1. Using Test A, we performed
29,161 pair-wise interaction tests among these 242 risk factor
SNPs (File S1 Supporting Figure 2), the results of which did not
deviate significantly from their empirical expected distribution
(Figure 2b). The most significant interaction (p=5.54610
26; see
File S1 Supporting Table 1) occurred between SNPs originally
reported to be associated with LDL cholesterol levels (rs2072183,
in NPC1L1) and smoking initiation (rs1013442, near BDNF). This
result did not exceed the significance threshold for this Analysis
(p=1.51610
26; Figure 2a; File S1 Supporting Table 2). Under an
interaction model with additive 6 additive effects, we estimated
Figure 1. Summary of subjects, methods and analyses. a. Number of SNP pairs for which interaction testing was performed - may not equal
the number of possible pair-wise tests [n*(n21)/2] because some pairs were captured in previous Analyses (File S1 Supporting Figure 2), and some
tests were not feasible due to low allele frequencies (File S1 Section 3.3). b. Significance threshold computed using permutations under the null
hypothesis (see File S1 Section 3.4) c. SNP pairs with p-value for interaction within 3 orders of magnitude of the significance threshold for each
Analysis were brought forward for validation in the WTCCC sample; the numbers of SNP pairs for which data were available in the WTCCC study are
shown. LDL, concentration of LDL cholesterol; HDL, concentration of HDL cholesterol; TG, triglyceride concentration; BP, blood pressure; CH,
carbohydrate metabolism (loci associated with risk of Type II diabetes and related phenotypes, such as fasting glucose concentration); SMK, smoking;
OB, obesity; small LDL, concentration of small atherogenic LDL particles; Lp(a), plasma levels of lipoprotein(a); CHD, risk of coronary heart disease; MI,
risk of myocardial infarction.
doi:10.1371/journal.pone.0041730.g001
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(OR) for interaction of between ,1.6 and ,1.3 when both SNPs
have a MAF of ,0.2 and ,0.5, respectively (Figure 2c; File S1
Supporting Table 3, File S1 Supporting Figure 4).
Analysis 2, Tests for Interaction between CVRF SNPs and
Marginal SNPs (p#10
23)
We selected 656 independent SNPs that showed moderate
marginal association (p#10
23) with MI in the MIGen study and
excluded 13 that had been captured in Analysis 1. Using Test A, we
Figure 2. Results of gene-gene interaction search among CVRF SNPs (Analysis 1). Panel A. Plot of the top result (arrow) from Analysis 1
against the distribution of the top results from 10,000 permutations under the null hypothesis (dotted line). The permuted top results are expected to
follow a beta-distribution (solid line, parameters obtained from permuted top results), the 95
th percentile of which was taken as the significance level
required to obtain a Type II error of 0.05 (arrow). Inset: While the significance level computed in Analysis 1 (dashed black line) was estimated using
10,000 null permutations, this estimate was found to stabilize rapidly with increasing number of permutations (black points) and to change little after
100–200 permutations. Consequently, we progressively reduced the number of permutations used to estimate the significance level in subsequent
Analyses. Panel B. Quantile-quantile plot showing rank-ordered observed results (black points) from 29,161 tests in Analysis 1 (y-axis) against
expected results (x-axis) estimated from 10,000 permutations under the null hypothesis (randomized phenotype). See File S1 Section 3.5 for
computation methods. The shaded area corresponds to the 95%CI of the permuted expected results. The 95%CI of a normal distribution is indicated
by the dotted lines. Panel C. Estimation of the interaction effect sizes this analysis has 80% power to detect across a range of MAF under an additive6
additive interaction model. The heights of the vertical bars correspond to the effect size (OR) detectable for a typical pair of SNPs whose MAFs are as
indicated on the horizontal axes.
doi:10.1371/journal.pone.0041730.g002
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SNPs and the 242 CVRF SNPs (File S1 Supporting Figure 2), the
results of which did not deviate significantly from their empirical
expected distribution (File S1 Supporting Figure 3). The most
significant result for interaction was p=9.48610
27, between SNPs
associatedwithHDLcholesterollevels(rs3136441,inLRP4)andMI
(rs9990208, located near RFTN1 and DAZL on chromosome 3,
p=1.2610
24inMIGen).Thisresultdidnotexceedthesignificance
threshold for this Analysis (p=3.13610
27; File S1 Supporting
Table2,FileS1Supporting Figure3).Underanadditive6additive
interaction model, this analysis was estimated to have highpower to
detect interaction effects of between ,1.7 and ,1.4 for SNPs with
MAF of ,0.2 and ,0.5, respectively (File S1 Supporting Table 3,
File S1 Supporting Figure 4).
Analysis 3a, Tests for Interaction among Marginal SNPs
(p#10
23)
For the 643 independent SNPs that achieved a p-value of #10
23
for association with MI in the MIGen study and that were not
captured in Analysis 1, we performed 201,537 pair-wise interaction
testsusingTestB(outofapossible206,403pairs;testnotfeasiblefor
4,866pairs(,2.35%)duetolowallelefrequencies,seeFileS1Section
3.3, File S1 Supporting Figure 2). The results of these tests did not
deviate significantly from their empirical expected distribution (File
S1SupportingFigure3).Themostsignificantp-valueforinteraction
was3.49610
26,betweenrs761174(withinHHATonchromosome1,
p=1.75610
25 in MIGen) and rs167490 (within CHST11 on
chromosome 12, p=5.92610
24 in MIGen), which did not exceed
the significance threshold for this Analysis (p=2.93610
27; File S1
Supporting Figure 3c). Under an additive 6 additive interaction
model, this analysis was estimated to have high power to detect
interactioneffectsofbetween,1.75and,1.4forSNPswithMAFof
,0.2 and ,0.5, respectively (File S1 Supporting Table 3, File S1
Supporting Figure 4).
Analysis 3b, Tests for Interaction among Marginal SNPs
(p#10
22)
Relaxingtheminimumthresholdoftheobservedmarginaleffects
of putative interacting SNPs, we selected 6,066 independent SNPs
that achieved a p-value of #10
22 for association with MI in the
MIGen study and that were not captured in the previous Analyses,
and performed 17,470,706 interaction tests, out of a possible
18,180,305 pairs (discarded 214,840 tests already captured by
previous Analyses; test not feasible for a further 709,599 (,3.9%)
pairs due to low allele frequencies, see File S1 Section 3.3, File S1
Supporting Figure 2). The results of these tests did not deviate
significantly from their empirical expected distribution (File S1
Supporting Figure 3). The most significant p-value for interaction
was 5.51610
28, between rs194243 (between CYP26B1 and
EXOC6B on chromosome 2, p=3.97610
23 in MIGen) and
rs4589969 (within CACNA2D3 on chromosome 3, p=7.75610
23
in MIGen), which did not exceed the significance threshold for this
Analysis (p=3.57610
29; File S1 Supporting Figure 3d). Under a
double-additive model, this analysis was estimated to have high
power to detect interaction effects of between ,1.85 and ,1.45 for
SNPswithMAFof,0.2and,0.5,respectively(FileS1Supporting
Table 3, File S1 Supporting Figure 4).
Validation of the Top Results from Analyses 1–3 in an
Independent Sample
While the minimum observed p-values in each Analysis were
,3–15 times larger than the corresponding significance threshold,
it is possible that real interaction effects are present but could not
be declared statistically significant because of the demanding
multiple testing burden. Therefore, we sought to validate our
findings for all SNP pairs that achieved a p-value for interaction
within 3 orders of magnitude of the required significance threshold
in each Analysis (File S1 Section 3.8). In a large sample of cases of
CHD and controls from the WTCCC (File S1 Section 1), we
replicated our analysis for 47, 49, 45 and 50 pairs of SNPs (out of
48, 52, 54 and 55 pairs that met this criterion) in Analyses 1, 2, 3a
and 3b, respectively. After correcting for multiple testing, none of
these pairs showed nominally significant evidence of interaction in
the WTCCC data (File S1 Supporting Table 2) for the SNP pairs
from Analysis 1 (pmin=0.0041; a<0.05/47<0.0011), Analysis 2
(pmin=0.0392; a<0.05/49<0.001), Analysis 3a (pmin=0.006;
a<0.05/45<0.001) or Analysis 3b (pmin=0.012; a<0.05/
50<0.001). Similarly, we observed no additional evidence of
interaction after performing a meta-analysis of both studies (see
File S1 Section 3.8 for methods and File S1 Supporting Table 2 for
results; Analysis 1, pmin=1.49610
25; Analysis 2,
pmin=1.41610
25; Analysis 3a, pmin=1.01610
24; Analysis 3b,
pmin=7.01610
27; significance thresholds equal to those for the
corresponding discovery Analyses, p=1.51610
26,
p=3.13610
27, p=2.93610
27, p=3.57610
29, respectively).
Discussion
In this paper, we searched for gene-gene interactions that
modify MI risk. Given the potentially large testing burden [21], we
sought to enrich our search space with real interactions by
analyzing variants that may be more likely to interact on the basis
of two distinct hypotheses: i) a biological hypothesis, under which
MI risk is modulated by the relationships between variants that are
known to be relevant for its risk factors or for MI/CHD risk
directly; and ii) a statistical hypothesis, under which the marginal
effects of true interactions are detectable as weak single locus
associations. We performed pair-wise SNP interaction testing in
three Analyses, first requiring that both potentially interacting
SNPs have highly significant effects on CHD risk or CV risk
factors (Analysis 1), then relaxing this requirement for one of the
SNPs, requiring that it be at least moderately associated with MI
(p#0.001; Analysis 2), and finally requiring that both SNPs have
only moderate (p#0.001) or weak (p#0.01) marginal association
with MI (Analyses 3a and 3b, respectively). No evidence for
interaction beyond that allowed for by chance was observed in any
of these analyses, and we observed no clear consistency between
the results for the most significant interactions in the discovery
sample and those in a large validation sample. Our study is among
the first to use GWAS data to investigate the role of epistasis as a
potential risk factor for myocardial infarction and related
phenotypes [22,23].
The search for epistatic effects that are relevant for complex
phenotypes can be, and has been, approached using a range of
strategies, more so than has been necessary for single-locus GWA
studies. Our study is not an exhaustive genome-wide search, but is
limited to two hypotheses about the nature of epistasis as a risk
factor for MI.
In relation to the first hypothesis, it seems reasonable to assume
that interactions that modulate cardiovascular risk are more likely
to occur between genes that are known to be relevant for
cardiovascular function than those that are not. A similar
reasoning formed the basis of a recent study of the role of epistasis
in modifying HDL cholesterol levels, in which the authors
searched for interactions between genes that were not only known
to be relevant for cardiovascular function but that also lie within
the same metabolic pathways [6]. Similarly, the most significant
Gene-Gene Interaction Analysis in MI
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occurred between variants that were previously shown to be
directly associated with diabetes risk [24]. Nonetheless, we note a
potential bias against finding interactions under this hypothesis
due to the fact that the initial discovery and replication of direct
associations between these SNPs and CVRFs might have been
possible precisely because these associations are not modulated by
interactions. However, given that the response phenotype in this
study is MI/CHD, the effect of this bias is probably limited to the
CHD-associated SNPs. A further limitation of our analysis under
the first hypothesis is the fact that we selected only the most
robustly associated CVRFs SNPs, so our analysis does not explore
potential interactions between other variants at these loci.
In relation to the second hypothesis, even in the absence of a
main effect, a SNP that modifies disease risk through interaction
must necessarily show some level of marginal risk effect because
some individuals will also carry the interacting allele of the other
SNP. This is true for all interaction models except those between
SNPs with balanced opposing effects on risk [25]; we believe that
such models are unlikely to be an important contributor to
heritability of complex phenotypes (but see ref [26]), and our
inability to detect them is compensated for by the increase in
power due to the reduced multiple testing burden. However, while
the reasoning for selecting SNPs with marginal effects is valid, it is
not clear how strong these marginal effects might be. Moreover,
they are expected to vary as a function of the mode of interaction
(e.g. dominant6dominant), and the frequencies and effect sizes of
the risk-associated compound genotypes. The thresholds of
marginal effect used in this study have been arbitrarily selected
for practical purposes.
In this study, interaction analyses were performed by using a
logistic regression framework to search for differences in the
distributions of the nine two-locus compound genotypes between
cases and controls, thereby assuming no specific interaction model.
Since the putative true interaction model is unknown, this model-
free approach aims to maximize power by encompassing all
possible interaction models, while requiring only one test for each
SNP pair; this gain in scope is expected to offset the loss of power
due to the additional degree of freedom. At any rate, for the top
SNP pairs from all three Analyses we also tested for interaction
under biologically meaningful interaction models (dominant 6
dominant, recessive 6recessive and additive 6additive, data not
shown), which, if true, would have higher power under H1, and
found no remarkably different results compared to those in which
no interaction model was assumed. In Analyses 1 and 2 we also
implemented a case-control/case-only test, which has previously
been reported to have higher power than the design we have
chosen; however, we observed very similar results for both designs
(see File S1 Note 1).
The negative results observed in our study may reflect one of
two possibilities. First, the role of gene-gene interactions in CHD
risk is negligible; this is contrary to the expectations of some
authors [27], and does seem unlikely given the complexity of
biological systems and the opportunities for interaction within and
between genes and pathways that are relevant for disease risk.
Conversely, the observation that interactions do not greatly modify
CHD risk would be consistent with the extensive redundancy
observed in biological systems, and with a recent study that
indicated the potential role of random variation in gene expression
in modulating the penetrance of interaction effects [28]. This
possibility is also consistent with the results of a study that provided
theoretical and experimental data to suggest that most of the
variance in complex traits is accounted for by additive effects [29],
and also possibly by the fact that genetic load, often represented as
a genetic score in the context of the results of GWAS studies, has
been observed to have generally linear effects on a range of
diseases and traits [30,31,32,33].
The second possible explanation for the negative results in this
study concerns the limitations of its design or size. The cross-
sectional nature of the MIGen study carries an inherent possibility
of survival bias, and although the early age of onset is expected to
enrich the cases’ genetic risk, this effect might be diluted by the
fact that the controls are age-matched and may represent future
cases. In addition, the WTCCC controls are represented by blood
donors whose CHD status may not have been well known, and by
recruits from the relatively young 1958 birth cohort who may yet
develop CHD. Moreover, given the large sample sizes required to
detect recently discovered single loci associated with MI/CHD
[3], our study might be expected to have limited power to detect
even more complex and potentially more subtle epistasis effects.
However, we estimate that this study is well powered to detect
interaction effects of a magnitude only slightly larger than those
observed for single loci in GWA studies (OR between 1.3 and 2,
depending on the interaction model and MAFs; see File S1
Supporting Table 3, File S1 Supporting Figure 4 and below). At a
minimum, our results do not support the existence of strong
epistasis effects as a common risk factor for CHD. The clinical
utility of data on interactions with more subtle effects may be
limited and would be difficult to detect with current strategies.
Nonetheless, this does not preclude the possibility that a very large
number of weaker and/or rarer interactions could account for a
significant portion of the variance in disease risk.
In this study, we used two approaches to distinguish between
true and false positives, as recommended by Yang et al. [18]. First,
we compared the p-values observed in our discovery sample to
their expected null distribution, which is a non-standard distribu-
tion due to the non-independence of the tests. The top result of a
large number of tests is known to follow a beta distribution, whose
parameters can be estimated by performing a large number of
permutations of all tests under the null hypothesis (randomized
case status), and taking the top result from each. The significance
level corresponding to the desired false positive rate within each
Analysis, taken as 0.05 in this study, is then equal to the 95
th
percentile of this beta distribution. We found that these parameters
stabilized after 200–300 permutations, which was practical when
using the –fast-epistasis function in PLINK [17], even for the
computationally intensive 3rd stage of analysis (,1.7610
7 tests).
This empirical approach to determining the global significance
level should be feasible for epistasis studies with even broader
scope than ours, such as that reported by Bell et al. [24], who
searched for interactions among ,70,000 tag-SNPs as a potential
risk factor for Type 2 diabetes. We note, however, that in all
Analyses the computed empirical significance levels were very
similar to those obtained using a Bonferroni correction (File S1
Section 7), suggesting that, at least in this study, little power would
be lost by assuming independence between tests. In fact, since any
one SNP will be uncorrelated with the vast majority of other SNPs,
and since we have specifically taken steps to ensure linkage
equilibrium between SNPs in each Analysis, it seems possible that
an initial assumption of independence between tests would be
entirely reasonable.
Second, we sought to validate the top results from our discovery
analysis in an independent sample. This approach essentially
represents a biological validation of the results in the discovery
stage, and is potentially useful when real effects are present but are
too subtle to overcome the multiple testing burden; consistent, but
not necessarily globally significant, results in the discovery and
validation analyses would constitute qualitative evidence for
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recently used as an alternative to the permutation-based approach
in order to verify the top results of a discovery analysis of gene-
gene interactions in relation to HDL cholesterol levels [6].
However, having observed entirely negative results in our
discovery analysis, deciding which strategy to use to select
interaction pairs to bring forward for validation is largely arbitrary.
To facilitate interpretation of our results, we performed post-hoc
power calculations. The most important determinants of the
power of any epistasis analysis are the true interaction effect sizes,
the interaction model, the frequency of the interacting variants
and the strength of LD between the true and observed variants, all
of which (apart from the latter, see below) are naturally
determined and beyond the control of experimental design. While
overall power can be optimized through modifiable determinants
of power, such as sample size and analytical strategy, any analysis
will have greater power to detect some epistasis models than
others. Given that the likely range of true interaction effect sizes is
unknown, we expressed the power of our analysis as the minimum
interaction effect size we had high power to detect (Type II error
=0.2), and performed this computation under various interaction
models and across a grid of allele frequency combinations
(Figure 2c, File S1 Supporting Table 3, File S1 Supporting Figure
4). While many different interaction models are possible [25], our
aim was to assess the range of power our study might have under
the intrinsically least powerful and most powerful models, recessive
6 recessive, and additive 6 additive, respectively (we also
computed power under a dominant 6 dominant model). For
each interaction model, and throughout the range of MAFs, these
computations result in a characteristic ’surface’ of effect sizes
(Figure 2c, File S1 Supporting Figure 4), at and above which our
study has high power to detect interactions. Moreover, note that
although power is lower for effect sizes below this surface, weaker
interactions could still be detected; for example, our study has 50%
power to detect effect sizes ,13% lower than those we have 80%
power to detect, and we might expect to discover approximately
half of such interactions. Finally, one of the most important
determinants of power that falls within the control of experimental
design to some extent is the strength of LD between the true causal
interacting variants and those analyzed. This is important for
epistasis analyses because increasing LD attenuates power to
detect non-additive effects faster than for additive effects (e.g. [16]),
such that complex effects may be essentially undetectable unless
they are captured with near-perfect LD. In this sense, the LD
pruning steps we have taken to minimize redundant testing may
actually have a greater negative effect on power than the gain in
power afforded by reducing the multiple-testing burden. For the
same reason the (non-additive) interaction model-free testing
framework (Test A) may have lower power than the additive test
(Test B), in addition to the power reduction due to the additional
degrees of freedom.
While this study was limited to testing second-order interactions,
as a preliminary exploration we performed a logic regression
analysis [34], which searches for higher order interactions using an
adaptive regression methodology, and which also provides
information on the level of interaction complexity that might best
explain the observed data (File S1 Note 2). The results of this
analysis generally indicated that little or no additional gain of
information was expected by exploring pair-wise, 3-, 4- or 5-way
interactions. These results are consistent with those of our main
analyses, indicating that higher order interactions may not play an
important role in population-wide disease risk population level. At
any rate, an exhaustive search for higher-order interactions was, of
course, beyond the scope of this study, as it would be for most
’genome-wide’ epistasis studies.
Conclusions
We have performed an extensive search for interactions
between SNPs that are robustly associated with classical CVRFs,
or that show marginal association with MI. Our results and post-
hoc power computations do not support the existence of strong
interaction effects as a common risk factor for MI in the general
population. This is consistent with the expectation that epistasis
effects will be difficult to detect for complex diseases. Within the
scope of the hypotheses we have explored, this study places a
modest upper limit on the risk effect sizes gene-gene interactions
are likely to have (OR for MI risk ,1.3–2.0, depending on allele
frequency and interaction model). While the discovery of gene-
gene interactions could provide important insights into molecular
function, considering the generally lower frequency and greater
complexity of these modest effects, their usefulness in driving drug
discovery and especially in improving cardiovascular risk assess-
ment may be limited.
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